Menu Search
Equities

Tsumura & Co

4540:TYO

Tsumura & Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,858.00
  • Today's Change35.00 / 0.73%
  • Shares traded158.50k
  • 1 Year change+78.93%
  • Beta0.6633
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy0
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 5 analysts offering 12 month price targets for Tsumura & Co have a median target of 5,000.00, with a high estimate of 6,470.00 and a low estimate of 4,400.00. The median estimate represents a 2.92% increase from the last price of 4,858.00.
High33.2%6,470.00
Med2.9%5,000.00
Low-9.4%4,400.00

Dividends in JPY

In 2024, Tsumura & Co reported a dividend of 85.00 JPY, which represents a 32.81% increase over last year. The 4 analysts covering the company expect dividends of 136.00 JPY for the upcoming fiscal year, an increase of 60.00%.
Div growth (TTM)32.81%
More ▼

Earnings history & estimates in JPY

On Nov 07, 2024, Tsumura & Co reported 2nd quarter 2025 earnings of 83.26 per share.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate+457.09%
Tsumura & Co reported annual 2024 earnings of 219.83 per share on May 09, 2024.
Average growth rate+5.94%
More ▼

Revenue history & estimates in JPY

Tsumura & Co. had 2nd quarter 2025 revenues of 45.38m. This missed the 46.00m consensus estimate of the 2 analysts following the company. This was 22.53% above the prior year's 2nd quarter results.
Average growth rate+5.24%
Tsumura & Co. had revenues for the full year 2024 of 150.85m. This was 7.71% above the prior year's results.
Average growth rate+5.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.